Gregory K. Palm
Directeur/Bestuurslid bij Olatec Therapeutics LLC
Actieve functies van Gregory K. Palm
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Directeur/Bestuurslid | 29-07-2021 | - |
Loopbaan van Gregory K. Palm
Eerdere bekende functies van Gregory K. Palm
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
THE GOLDMAN SACHS GROUP, INC. | Algemeen Adviseur | 01-05-1992 | - |
Bedrijfssecretaris | 01-05-1992 | - |
Opleiding van Gregory K. Palm
Harvard Business School | Graduate Degree |
Massachusetts Institute of Technology | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
General Counsel | 1 |
Corporate Secretary | 1 |
Director/Board Member | 1 |
Sectoraal
Finance | 3 |
Health Technology | 2 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
THE GOLDMAN SACHS GROUP, INC. | Finance |
Bedrijven in privébezit | 1 |
---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
- Beurs
- Insiders
- Gregory K. Palm
- Ervaring